TALLC is a pre-clinical stage biopharmaceutical company developing our new mechanism medicines to treat acute and chronic conditions in the eye.
To Improve the Lives of Patients by Inventing and Developing Valuable New Ophthalmic Medicines
To be a leading provider of pipeline opportunities in ophthalmics enabling better clinical and commercial outcomes.
Our pipeline of new mechanism synergistic API, enabled for pan-ocular delivery by our SmartCelleTM and AmyloFlexTMdelivery platforms, developed by our expert team of scientist and industry professionals.
Largely virtual, the high experienced TALLC team will first focus on SmartCelle TA-A001, a micellar formulation of our novel CB2 receptor specific drug candidate:
As a topically instilled eye drop for the severe pain and inflammation that occurs after cross-linking surgery for keratoconus
- As a topical treatment to avoid the pain and inflammation resulting from PRK, LASIK, SMILE and Cataract surgeries
- TALLC is also developing extended release formulations of our pipeline candidates for treatment of Dry-Eye Disease, Uveitis, AMD and Glaucoma
Meet the team
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020